First single-dose medicine for P. vivax malaria prequalified by WHO and included in WHO Guidelines
|
05 December 2024 |
GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline
|
01 November 2024 |
GSK and CureVac to restructure collaboration into new licensing agreement
|
03 July 2024 |
GSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies
|
06 June 2024 |
GSK and Save the Children renew award-winning partnership, with focus on 'zero dose' children who have never received a vaccine
|
14 September 2023 |
New research published in Science highlights potential of a naturally occurring bacterium to help eradicate malaria
|
03 August 2023 |
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
|
19 April 2023 |
US FDA Advisory Committee votes to support effectiveness and safety of GSK's respiratory syncytial virus older adult vaccine candidate
|
06 March 2023 |
GSK announces results from 17-year retrospective study on US clinical trial diversity
|
09 February 2023 |
VidPrevtyn Beta COVID-19 booster vaccine, developed by Sanofi and GSK, approved for use in Great Britain
|
28 December 2022 |